title: Daily omeprazole surpasses intermittent dosing in preventing relapse of oesophagitis: a US multi-centre double-blind study.
abstract: BACKGROUND
  Relapse of erosive oesophagitis occurs in almost all patients if treatment is stopped after initial healing.
  
  
  OBJECTIVE
  To assess the potential of different therapeutic regimens of omeprazole to prevent relapse of erosive reflux oesophagitis after initial healing with omeprazole.
  
  
  METHODS
  Patients whose active erosive reflux oesophagitis (grade > or = 2) had healed (grade 0 or 1) after 4-8 weeks of open-label omeprazole 40 mg daily (phase I) were eligible to join a multi-centre, 6-month double-blind, placebo-controlled maintenance study (phase II), which included endoscopy, symptom assessments, serum gastrin measurements, and gastric fundic biopsies. During phase I, endoscopy was performed at weeks 0, 4, and 8. At the end of phase I, 429 of 472 patients (91%) were healed, and there were significant reductions in heartburn, dysphagia and acid regurgitation. Of the 429 patients who healed, 406 joined phase II and were randomized to one of three groups: 20 mg omeprazole daily (n = 138), 20 mg omeprazole for 3 consecutive days each week (n = 137), or placebo (n = 131). During phase II, endoscopy was performed at months 1, 3, and 6 or at symptomatic relapse.
  
  
  RESULTS
  The percentages of patients still in endoscopic remission at 6 months were 11% for placebo, 34% for omeprazole 3-days-a-week, and 70% for omeprazole daily. Both omeprazole regimens were superior to placebo in preventing recurrence of symptoms (P < 0.001); however, omeprazole 20 mg daily was superior to omeprazole 20 mg 3-days-a-week (P < 0.001). Compared to baseline, omeprazole therapy resulted in no significant differences among treatment groups in the distribution of gastric endocrine cells.
  
  
  CONCLUSIONS
  These results show that after healing of erosive oesophagitis with 4-8 weeks of omeprazole, relapse of oesophagitis and recurrence of reflux symptoms can be prevented in 70% of patients with a maintenance regimen of 20 mg daily, but that intermittent dosing comprising 3 consecutive days each week significantly compromises efficacy.
authors.affiliation: Medical Service, VA Medical Center, Hines, IL 60141, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Sontag
authors.forename: M
authors.initials: M
authors.lastname: Robinson
authors.forename: W
authors.initials: W
authors.lastname: Roufail
authors.forename: B I
authors.initials: BI
authors.lastname: Hirschowitz
authors.forename: S M
authors.initials: SM
authors.lastname: Sabesin
authors.forename: W C
authors.initials: WC
authors.lastname: Wu
authors.forename: J
authors.initials: J
authors.lastname: Behar
authors.forename: W L
authors.initials: WL
authors.lastname: Peterson
authors.forename: K R
authors.initials: KR
authors.lastname: Kranz
authors.forename: A
authors.initials: A
authors.lastname: Tarnawski
authors.forename: Y
authors.initials: Y
authors.lastname: Dayal
authors.forename: R
authors.initials: R
authors.lastname: Berman
authors.forename: T J
authors.initials: TJ
authors.lastname: Simon
mesh_terms: D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence
chemical_list: D000897:Anti-Ulcer Agents; D009853:Omeprazole